FDA advisers vote that lecanemab shows benefit as an Alzheimer's treatment | Health

An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer's drug lecanemab shows "clinical benefit" for the treatment of the disease, paving the way

Related Keywords

United States ,Massachusetts ,Americans ,Teresa Buracchio ,James Galvin ,Michael Abrams ,Joanne Pike ,Michael Irizarry ,Office Of Neuroscience ,Central Nervous System Drugs Advisory Committee ,Numerof Associates ,Brain Health ,Kaiser Family Foundation ,Centers For Medicare ,Discovery Company ,Warner Bros ,Drug Administration ,Advisory Committee ,University Of Miami Health System ,Medicaid Services ,Alzheimer Association ,Cable News Network Inc ,Chiquita Brooks Lasure ,Comprehensive Center ,Miami Health System ,Merit Cudkowicz ,Massachusetts General Hospital ,Michael Gold ,Kaiser Family ,Medicare Advantage ,News Network ,